Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
Open Access
- 18 June 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 60 (3) , 613-618
Abstract
Although inadequate antimicrobial therapy has been demonstrated in multiple studies to increase the risk for death in bacterial infections, few data investigating the effect of antifungal therapy on outcome of serious fungal disease are available. We sought to assess the adequacy of empirical therapy and its effect on mortality in invasive Candida species infections. Population-based surveillance of all patients with Candida spp. cultured from blood and/or cerebrospinal fluid was conducted. Adequacy of empirical therapy was assessed according to published guidelines. During a 5 year period, 207 patients had an invasive Candida spp. infection identified; in 199 cases (96%) adequate data were available for assessment of treatment and outcome at hospital discharge. One hundred and three (52%) cases were due to Candida albicans, 44 (22%) were due to Candida glabrata and the remainder were due to other species. Between the time of culture draw and reporting of a positive culture, only 64 (32%) patients were treated with empirical therapy; this was deemed adequate in 51 (26%). Patients who received adequate empirical therapy had a significant decrease in crude mortality [14/51 (27%) versus 68/148 (46%); risk ratio 0.60 (95% confidence interval 0.37–0.96); P = 0.02]. After adjusting for age and the need for intensive care unit admission in logistic regression analysis, the use of adequate empirical therapy was independently associated with a reduced risk for death [odds ratio 0.46 (95% confidence interval 0.22–1.00); P = 0.05]. Adequate empirical therapy is used in a minority of patients with invasive Candida spp. infections but is associated with improved survival.Keywords
This publication has 31 references indexed in Scilit:
- Invasive CandidiasisInfectious Disease Clinics of North America, 2006
- Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida speciesBMC Infectious Diseases, 2005
- Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance StudyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for DeathEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Systemic candidiasis in intensive care units: A multicenter, matched-cohort studyJournal of Critical Care, 2002
- Secular Trend of Hospital‐Acquired Candidemia among Intensive Care Unit Patients in the United States during 1989–1999Clinical Infectious Diseases, 2002
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year AnalysisClinical Infectious Diseases, 1999
- The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of IllnessClinical Infectious Diseases, 1998
- Hospital-Acquired CandidemiaArchives of internal medicine (1960), 1988